High Weekly Volatile Stocks: Hortonworks Inc (HDP), Freshpet Inc (FRPT), And Tekmira Pharmaceuticals Corporation (TKMR)

Posted by Ryan Mandell January 8, 2015 0 Comment 757 views

New York, NY – GDP INSIDER  – 01/08/2014.

A 25-day cool-off period set by SEC for Hortonworks Inc (NASDAQ:HDP) finally ended, and the stock is expected to remain volatile for some time. That is because underwriters in the company’s $100 million IPO now go live with their recommendations. RBC Capital Markets, one of the IPO underwriters, initiated the stock with an “Outperform” rating and set $31 target price on it.

The other underwriters in the IPO of Hortonworks include Credit Suisse and Goldman Sachs Group Inc (NYSE:GS).

Hortonworks Inc (NASDAQ:HDP) has a strong client base, which is expected to support big revenue growth.

Will HDP Continue To Trend Higher Or Are Things About To Crash? See What’s Coming Up Next For HDP With A Complimentary Trend Analysis Report

There are recent developments in Freshpet Inc (NASDAQ:FRPT) that call for close investor attention in the stock, because of their potential impact on the share price. The addition of Freshpet to the Russell 2000 Index and Russell 3000 Index, for instance, are expected to increase the visibility of the stock in the market. While the inclusion in the indices is a positive development, the increased visibility may not be good enough if the company fails to live up to the expectations.

Although Freshpet Inc (NASDAQ:FRPT) improved its bottom line in the most recent quarter, the company fell short of the consensus estimate. It will need to do more to improve investor confidence.

Is FRPT Going To Continue To Move Higher Or Are Things About To Turn Around? See What’s In Store For FRPT With A Free Trend Report.

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) recently offered positive update about the clinical trials of its drug candidate TKM-PLK1. It said that it had completed enrollments for the study. The company further revealed that some 55 patients have so far treated.

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) continues to collect data in the trials, but has noted positive indications, especially anti-tumor activity. Final data from the trial of TKM-PLK1 is expected in mid-2015.

Meanwhile, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) will supply its investigational Ebola drug for trial in West African by a group of institutions that include the Oxford University of England. TKM-Ebola-Guinea is designed to combat the effects of the Ebola strain that is causing havoc in West Africa.

Will TKMR Continue To Move Higher Or Are Things About To Reverse? See What Is Next For TKMR With A Free Trend Analysis

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment